Results 201 to 210 of about 123,523 (307)

Guideline-Directed Medical Therapy Intensity, Ventricular Remodeling, and Clinical Outcomes After Acute Myocardial Infarction: A Single-Center Real-World Retrospective Cohort Study. [PDF]

Biomedicines
Mateoc-Sîrb T, Suciu IM, Gaiță D, Minodora A, Popescu R, Vlad T, Muntean C, Vlad DC.   +7 more
europepmc   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Development and multicentre validation of an artificial intelligence electrocardiogram model for ventricular remodeling in repaired tetralogy of Fallot. [PDF]

Eur Heart J Digit Health
Duong SQ, Vaid A, Jiang P, Bitterman Y, Krishnamurthy Y, Chiu IM, Finer J, Cleary B, Glicksberg BS, Garg R, DiLorenzo M, Friedberg M, Zahn E, Lewis M, Satzer M, Ouyang D, Elias P, Geva T, Ghelani S, Anderson BR, Zaidi A, Wald RM, Nadkarni GN, Mayourian J.   +23 more
europepmc   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

ESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin, Magnus Bäck, Anders Franco‐Cereceda, Sven‐Christian Pawelzik   +3 more
wiley   +1 more source

Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation. [PDF]

Int J Mol Sci
Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H, Martínez Mas ML, Climent Alberola JI, López-Bueno L, Payá Rubio A, Pérez-Solé N, Ríos-Navarro C, de Dios E, Gavara J, Moratal D, Rodriguez-Palomares JF, Ortiz-Pérez JT, Sanchis J, Bodi V.   +15 more
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Activation of α7nAChR prevents maladaptive right ventricular remodeling via inhibiting the recruitment of CCR2⁺ macrophages in experimental pulmonary arterial hypertension. [PDF]

Respir Res
Chen K, Li Z, Lu J, Guo Y, Xie H, Wu F, Wu W.   +6 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Shuxuening injection improves ventricular remodeling after myocardial infarction by indirectly promoting macrophage-mediated angiogenesis and lymphangiogenesis. [PDF]

Chin Med
Yang L, Zhang X, Zheng Y, Wang H, Zhang M, Wu Y, Zhang H, Wang X, Cao Y, Wang P, Wang B, Wei S, Li Y, Li W, Chen X, Tang J.   +15 more
europepmc   +1 more source